White Paper

Optimizing Drug Safety And Efficacy Of Complex Next-Generation Biologics

Source: Cytiva
Antibody Drug Conjugate Services (ADC)

In recent years, the global biopharma industry has seen a rapidly advancing trend toward biotherapeutics or “biologics drugs” — drugs that are produced from living organisms or contain components of living organisms.(1) In 2018 alone, the U.S. FDA approved 17 biologics out of a total of 59 drugs – the highest number to date.(2)

Due to their ability to effectively treat complex health problems like cancer, infectious diseases, and autoimmune diseases, biologics have become a major focus for most pharmaceutical companies.(3) Additionally, the FDA facilitates approval of many biologics through expedited programs, making the ventures even more lucrative to Big Pharma. Last year, six of the 15 best-selling drugs were biologics.(4)

This article will delve into why the pharma industry is heading toward a biologics revolution, what challenges exist when developing these drugs to be efficacious but safe, and how novel analytical techniques can help circumvent these issues and optimize development.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: